Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 specific T cells (KK Women's and Children's Hospital)
- Development stage
- Unknown
- Lead developer
- KK Women's and Children's Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
SARS-CoV-2 specific T cells (KK Women's and Children's Hospital) is an adoptive cell therapy consisting of virus-specific T cells derived from convalescent or vaccinated donors. Developed by KK Women's and Children's Hospital in collaboration with Singapore General Hospital and the National University of Singapore, the therapy is designed to treat severe or high-risk COVID-19 in immunocompromised patients, including those with hematological malignancies or transplant recipients. The product consists of T cells enriched for interferon-gamma (IFN-γ) secretion that specifically target the spike (S), nucleocapsid (N), and membrane (M) proteins of the SARS-CoV-2 virus. These third-party donor cells are HLA-matched to the recipient and administered via intravenous infusion to augment the patient's cellular immunity against the virus.
- Other names
- SARS-CoV-2 Specific T CellsSARS-CoV2 Specific T CellsSARS-CoV 2 Specific T CellsAdoptive T-cell therapy for COVID-19
02
Targets
SARS-CoV-2 spike peptide–Major Histocompatibility Complex (SARS-CoV-2 spike–MHC)SARS-CoV-2 N protein MHC-I epitopes (SARS-CoV-2 nucleocapsid protein MHC class I epitopes)M protein (SARS-CoV-2 membrane protein)
Beyond the preview
Go deeper on SARS-CoV-2 specific T cells (KK Women's and Children's Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 specific T cells (KK Women's and Children's Hospital).